MedWatch

Danish biotech company raises 60 million for psoriasis drug

A Danish biotech company is on the verge of marketing a new drug candidate. A financing round that generated millions is set to help the company reach its target.

Zealand Pharma is not the only biotech company to take a candidate drug all the way to the market. Another Danish biotech company could now be going global with a new psoriasis drug.

Forward Pharma has recently secured 60 million kroner (USD 10.35 million) from existing investors to be used to bring the candidate drug FP 187 to international markets – initially aimed at psoriasis patients, it will also be used to treat sclerosis later on.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier